DK0946157T3 - Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte - Google Patents
Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerteInfo
- Publication number
- DK0946157T3 DK0946157T3 DK97954571T DK97954571T DK0946157T3 DK 0946157 T3 DK0946157 T3 DK 0946157T3 DK 97954571 T DK97954571 T DK 97954571T DK 97954571 T DK97954571 T DK 97954571T DK 0946157 T3 DK0946157 T3 DK 0946157T3
- Authority
- DK
- Denmark
- Prior art keywords
- kappa
- treatment
- topical use
- opioid agonists
- eye pain
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title abstract 2
- 206010015958 Eye pain Diseases 0.000 title 1
- 229940127450 Opioid Agonists Drugs 0.000 title 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 108020001588 κ-opioid receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3290996P | 1996-12-16 | 1996-12-16 | |
| PCT/US1997/023185 WO1998026770A2 (en) | 1996-12-16 | 1997-12-11 | The topical use of kappa opioid agonists to treat ocular pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0946157T3 true DK0946157T3 (da) | 2002-07-08 |
Family
ID=21867521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97954571T DK0946157T3 (da) | 1996-12-16 | 1997-12-11 | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6191126B1 (da) |
| EP (1) | EP0946157B1 (da) |
| JP (2) | JP2001506652A (da) |
| AT (1) | ATE214272T1 (da) |
| AU (1) | AU731447B2 (da) |
| CA (1) | CA2275167C (da) |
| DE (1) | DE69711078T2 (da) |
| DK (1) | DK0946157T3 (da) |
| ES (1) | ES2174337T3 (da) |
| HK (1) | HK1020867A1 (da) |
| PT (1) | PT946157E (da) |
| WO (1) | WO1998026770A2 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6191126B1 (en) | 1996-12-16 | 2001-02-20 | Alcon Laboratories, Inc. | Topical use of κ opioid agonists to treat ocular pain |
| AU1828399A (en) * | 1997-12-22 | 1999-07-12 | Alza Corporation | Novel formulations for the transdermal administration of asimadoline |
| ATE344035T1 (de) | 1998-07-16 | 2006-11-15 | Memorial Sloan Kettering Inst | Topische zusammensetzung enthaltend ein opioid- analgetikum und einen nmda-antagonisten |
| WO2000072835A2 (en) * | 1999-05-27 | 2000-12-07 | El Khoury George F | Topical application of muscarinic and opioid agents for treatment of tinnitus |
| US6174878B1 (en) | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
| AU2001257326A1 (en) | 2000-04-28 | 2001-11-12 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| US7820688B2 (en) * | 2001-04-27 | 2010-10-26 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| DE10259245A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20060069086A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| CA2869280C (en) * | 2011-04-05 | 2020-03-10 | Optosolve Llp | Ophthalmic treatments |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| FR3044227B1 (fr) * | 2015-11-30 | 2017-11-24 | Pharmaleads | Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires |
| EP3932390A1 (en) * | 2020-07-02 | 2022-01-05 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Topical gel formulation containing asimadoline |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2632520B1 (fr) | 1988-06-10 | 1990-09-14 | Rhone Poulenc Sante | Derives de la phenothiazine analgesiques |
| US4939135A (en) | 1988-10-03 | 1990-07-03 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation |
| US5360611A (en) | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| FR2646773B1 (fr) | 1989-05-12 | 1994-05-13 | Chauvin Sa Laboratoire | Composition pharmaceutique a base de paracetamol |
| JPH06122677A (ja) | 1992-08-28 | 1994-05-06 | Sankyo Co Ltd | 光学活性なカルボン酸アミド誘導体 |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| US5688955A (en) | 1996-03-08 | 1997-11-18 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| US6191126B1 (en) | 1996-12-16 | 2001-02-20 | Alcon Laboratories, Inc. | Topical use of κ opioid agonists to treat ocular pain |
-
1997
- 1997-12-11 US US09/319,064 patent/US6191126B1/en not_active Expired - Lifetime
- 1997-12-11 AT AT97954571T patent/ATE214272T1/de active
- 1997-12-11 EP EP97954571A patent/EP0946157B1/en not_active Expired - Lifetime
- 1997-12-11 DK DK97954571T patent/DK0946157T3/da active
- 1997-12-11 PT PT97954571T patent/PT946157E/pt unknown
- 1997-12-11 WO PCT/US1997/023185 patent/WO1998026770A2/en active IP Right Grant
- 1997-12-11 DE DE69711078T patent/DE69711078T2/de not_active Expired - Lifetime
- 1997-12-11 JP JP52790398A patent/JP2001506652A/ja not_active Withdrawn
- 1997-12-11 CA CA002275167A patent/CA2275167C/en not_active Expired - Lifetime
- 1997-12-11 ES ES97954571T patent/ES2174337T3/es not_active Expired - Lifetime
- 1997-12-11 AU AU58987/98A patent/AU731447B2/en not_active Expired
-
1999
- 1999-11-27 HK HK99105517A patent/HK1020867A1/xx not_active IP Right Cessation
-
2008
- 2008-11-04 JP JP2008282744A patent/JP2009067806A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69711078T2 (de) | 2002-10-02 |
| US6191126B1 (en) | 2001-02-20 |
| EP0946157A2 (en) | 1999-10-06 |
| CA2275167C (en) | 2008-10-28 |
| DE69711078D1 (de) | 2002-04-18 |
| JP2009067806A (ja) | 2009-04-02 |
| CA2275167A1 (en) | 1998-06-25 |
| WO1998026770A3 (en) | 1998-09-03 |
| JP2001506652A (ja) | 2001-05-22 |
| HK1020867A1 (en) | 2000-05-26 |
| ATE214272T1 (de) | 2002-03-15 |
| WO1998026770A2 (en) | 1998-06-25 |
| AU5898798A (en) | 1998-07-15 |
| EP0946157B1 (en) | 2002-03-13 |
| ES2174337T3 (es) | 2002-11-01 |
| PT946157E (pt) | 2002-07-31 |
| AU731447B2 (en) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
| IS6560A (is) | Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni | |
| WO2001015678A3 (en) | Topical use of kappa opioid agonists to treat otic pain | |
| TR199901172T2 (xx) | Yeni ikame edilmi� pirazol t�revleri. | |
| BR0307508A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença | |
| RS50091B (sr) | Upotreba retigabina u lečenju neuropatskog bola | |
| TR200909479T2 (tr) | Sinerjistik kombinasyon. | |
| PT957914E (pt) | Formulacao de agonistas de 5-ht | |
| TR199901417T2 (xx) | Analjezik etkisi olan yeni bile�imler. | |
| HK1051324A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity. | |
| BR0313239A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças | |
| YU13301A (sh) | Muskarinski agonisti i antagonisti | |
| SE9603725D0 (sv) | New teatment | |
| IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
| EE200100689A (et) | IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon | |
| MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
| ATE344664T1 (de) | Verbesserte methode zur eradikation von helicobacter pylori | |
| ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
| EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА | |
| BR0214060A (pt) | Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática | |
| DE60009315D1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
| NO20005548D0 (no) | Mykobakterieinhibitorer | |
| BG105984A (bg) | Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението | |
| NO984651D0 (no) | Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet | |
| DK1052991T3 (da) | Topisk anvendelse af loperamid til behandling af mikrobielle infektioner |